Definition and natural history of metabolic steatosis: Clinical aspects of NAFLD, NASH and cirrhosis

Diabetes and Metabolism

Volumn 34, Issue 6 PART 2, 2008, Pages 634-637

  Serfaty, L ^a,b   Lemoine, M ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

Author keywords

Cirrhosis; Diabetes; Hepatocellular carcinoma; Insulin resistance; Metabolic steatosis; Metabolic syndrome; NAFLD; NASH; Obesity; Review; Unexplained cytolysis

Indexed keywords

ADULT; ARTICLE; CLASSIFICATION; DISEASE COURSE; EUROPE; FATTY LIVER; HUMAN; INCIDENCE; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TUMOR; PATHOPHYSIOLOGY; PREVALENCE; UNITED STATES;

ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EUROPE; FATTY LIVER; HUMANS; INCIDENCE; JAPAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; PREVALENCE; UNITED STATES;

EID: 62749144547     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(08)74597-X     Document Type: Article

References (27)

1. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
2. Ludwig J, Viggiano T, McGill D, Ott B. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
3. Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut 1985;26:133-9.
4. Nomura F, Ohnishi K, Satomura Y, Ohtsuki T, Fukunaga K, Honda M, et al. Liver function in moderate obesity:study in 534 moderately obese subjects among 4,613 male company employees. Int J Obes 1986;10:349-54.
5. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-7.
6. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-9.
7. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
8. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
9. de Lédinghen V, Ratziu V, Causse X, Le Bail B, Capron D, Renou C, et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol 2006;45:592-9.
10. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792-8.
11. Fartoux L, Serfaty L. Vers une approche métabolique de l'hépatite C. Gastroenterol Clin Biol 2007;31:639-40.
12. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-31.
13. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-9.
14. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
15. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-73.
16. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein- calorie malnutrition. Gastroenterology 1982;82:535-48.
17. Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A populationbased cohort study. Gastroenterology 2003;125:1053-9.
18. Calle EE. Obesity and cancer. BMJ 2007;335:1107-8.
19. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-61.
20. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
21. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-8.
22. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
23. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
24. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93.
25. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis (letter). Gastroenterology 1995;108:1607.
26. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
27. Serfaty L. Pioglitazone:the beginning of a new era for NASH? J Hepatol 2007;47:160-2.